Body Sculpting
Conditions
Keywords
focused ultrasound, mechanical fat destruction, Body Sculpting
Brief summary
The primary objective of this study is to evaluate the effectiveness of the Contour I VER 3.1 System on abdominal midsection circumference reduction relative to no treatment. The secondary objective of this study is to assess subject satisfaction measured with a self-assessment questionnaire
Interventions
DEVICENon Invasive Ultrasound
Each treatment session is estimated to take approximately 60 minutes and will be performed on a bi-weekly basis.
Sponsors
Syneron Medical
UltraShape
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Female or male subjects, 18 and 65 years of age at the time of enrollment 2. Abdominal fat thickness of at least 1.5 cm (measurement by caliper) 3. For women of child-bearing potential: 1. negative urine pregnancy test. 2. Women of child bearing age are required to be using an acceptable form of birth control for the duration of the study. 4. General good health confirmed by medical history and skin examination of the treated area 5. Written informed consent to participate in the study 6. Ability to comply with the requirements of the study 7. BMI ≤ 30 Intra-procedural Inclusion criteria (prior to starting the treatment phase): subjects are eligible to continue the study and participate in the treatment phase if she meets all of the following intra-procedural inclusion criteria: 8. For women of child-bearing potential: negative pregnancy test 9. Abdominal fat thickness of at least 1.5 cm prior to initial treatment (measurement by caliper)
Exclusion criteria
1. History of hypertension, ischemic heart disease, valvular heart disease, congestive heart failure, pacemaker/defibrillator, abdominal aortic aneurysm 2. Current hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease or malignancy. 3. Previous liposuction in the treatment area 4. History of skin disease in the treatment area, known tendency to form keloids or poor wound healing 5. Skin lesions in the treatment area other than simple nevi on physical examination (e.g., atypical nevus, tattoo, abrasions) including depressed scars in the treatment area 6. Poor skin quality (i.e., laxity) 7. Abdominal wall diastasis or hernia on physical examination 8. Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count within the last 3 months 9. Obesity (BMI \> 30) 10. Childbirth within the last 12 months or breastfeeding women. 11. Any acute or chronic condition which, in the opinion of the Investigator, could interfere with the conduct of the study 12. Unstable weight within the last 6 months (i.e., ± 3% weight change in the prior six months) 13. Inability to comply with circumference measurement procedure (e.g., inability to held breath for the required duration) 14. Participation in another clinical study within the last six months. 15. Previous body contouring treatments in the areas of the abdomen and flanks.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary objective of this study is to evaluate the effectiveness of the Contour I VER 3.1 System on abdominal midsection circumference reduction relative to no treatment | 5-6 months | Reduction in circumference measurement of the abdomen from baseline |
Secondary
| Measure | Time frame |
|---|---|
| Assess subject satisfaction measured with a self-assessment questionnaire | 5-6 months |
Countries
Israel, United States
Outcome results
None listed